<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958617</url>
  </required_header>
  <id_info>
    <org_study_id>1648</org_study_id>
    <nct_id>NCT03958617</nct_id>
  </id_info>
  <brief_title>Thalamic Deep Brain Stimulation for Tourette Syndrome</brief_title>
  <official_title>Thalamic Deep Brain Stimulation for Tourette's Syndrome: a Pragmatic Trial With Brief Randomized, Double-blinded Sham Controlled Sequences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this single-center trial, we aim to include 8 patients with severe and medically
      refractory Tourette's syndrome. All patients undergo deep brain stimulation surgery with two
      electrodes located in the centromedian-parafascicular complex. Tic severity and secondary
      outcome measurements are assessed six and twelve months after surgery. Additionally, a short
      randomized, double-blinded sham controlled crossover sequence of 24 to 48 hours in either
      active or sham stimulation is implemented after both 6 and 12 months assesments. Subjects and
      clinicians are blinded to treatment allocation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2014</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A pragmatic trial with brief randomized, double-blinded sham controlled sequences</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Change in the YGTSS Scale from Baseline to 6 and 12 months</time_frame>
    <description>Motor tic subscore range 0-25 Vocal tic scubscore range 0-25 Impairment range0-50 Total Score (Vocal tic score + Motor tic score + Impairment) range 0-100
Higher Scores indicate higher tic severity, thus worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rush video rating scale (MRVRS)</measure>
    <time_frame>Change in the MRVRS Scale from Baseline to 6 and 12 months</time_frame>
    <description>Range 0-20
Higher Scores indicate higher tic severity, thus worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>On condition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ongoing thalamic deep brain stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off condition</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Switched off thalamic deep brain stimulation, sham stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilateral Deep brain stimulation of the thalamus, Medtronic Device</intervention_name>
    <arm_group_label>Off condition</arm_group_label>
    <arm_group_label>On condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Das Tourette-Syndrom (ICD-10: F 95.2; DSM IV: 307.23) als Hauptdiagnose. Bei dem
             Patienten ist aufgrund einer chronischen, schwergradigen und therapieresistenten
             Verlaufsform des TS eine Behandlung mittels THS thalamischer Strukturen im Sinne einer
             ultima ratio vorgesehen.

          -  Alter des Patienten 18 bis 65 Jahre

          -  Sicher im Verstehen der deutschen Sprache

          -  Unterzeichnete Einverständniserklärung

        Exclusion Criteria:

          -  Klinisch manifeste Psychose

          -  Schwangerschaft und Stillzeit

          -  Unterbringung nach PsychKG

          -  Kontraindikationen einer MRT-Untersuchung wie z. B. implantierter Herzschrittmacher /
             Defibrillator

          -  Neoplastische neurologische Erkrankungen

          -  Kontraindikationen einer stereotaktischen Operation, wie z. B.: erhöhte
             Blutungsneigung, cerebrovaskuläre Erkrankungen (z. B. arteriovenöse Malformationen,
             Aneurysmata, systemische Gefäßerkrankungen, die auf das Cerebrum übergreifen).

          -  Teilnahme an einer anderen klinischen Studie

          -  Hirnassoziierte Kriterien, die eine OP ausschließen (Gefäßanomalien, große
             arteriovenöse Malformationen, Hirnmetastasen, Neoplasien des ZNS (Ausnahme
             asymptomatisches inzidentielles Meningeom))

          -  Antikoagulationtherapie, die in der perioperativen Phase nicht ausgesetzt werden kann

          -  OP am Gehirn in der Anamnese, die mit der Platzierung/Funktion des MP interferieren

          -  Med. Gegebenheiten, die mit der Studienprozedur interferieren oder Evaluation der
             Studienparameter beeinträchtigen inkl. Erkrankungen im terminalen Stadium
             (Lebenserwartung &lt; 12 Monate)

          -  Akute Suizidalität

          -  Abhängigkeit von Alkohol oder Drogen (exklusive Cannabis, da es von schwer betroffenen
             Patienten teilweise zur Ticreduktion im Sinne einer Selbstmedikation eingesetzt wird
             sowie exklusive Opioide und Benzodiazepine, wenn diese initial zur Ticreduktion im
             Sinne einer Selbstmedikation eingesetzt wurden)

          -  Klinisch relevante internistische oder neurologische Erkrankungen

          -  Intelligenzminderung

          -  Alle aktiv implantierten Medizinprodukte

          -  Schweres Schädel-Hirn-Trauma in der Anamnese

          -  Metallimplantate im Kopfbereich ( Bsp. Aneurysmaclips)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kuhn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Jens Kuhn</investigator_full_name>
    <investigator_title>P.I.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

